New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

As weight-loss drugs are gaining popularity among Indian diabetes and obesity stricken patients in India, new research highlights rare but serious eye risks linked to the blockbuster GLP-1 medications ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...

Obesity is a worldwide problem that is increasing. It also is associated with ocular problems. A recent study found that in ...

In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy ...

In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Tirzepatide, sold under the name Zepbound, activates two hormone receptors—GLP-1 and GIP—while semaglutide (Wegovy) only targets GLP-1. Both of these hormones help reduce appetite and regulate ...